MEDIPAL HOLDINGS CORPORATION

Representative: Shuichi Watanabe, Representative Director, President and CEO Code number: 7459 (Prime Market, Tokyo Stock Exchange)

Contact: Yuji Sakon,

Managing Director, General Manager of Administration Division

Tel: +81-3-3517-5171

Notice Regarding Results and Completion of Acquisition of Treasury Stock and Number of Cancellation Shares of Treasury Stock

MEDIPAL HOLDINGS CORPORATION ("MEDIPAL") hereby announces to have carried out a market purchase as below and which has ended, regarding the acquisition of treasury stock based on the provisions of the Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act, which was resolved at the Board of Directors meeting held on May 13, 2025. And MEDIPAL announces total number of shares to be canceled regarding the cancellation of treasury stock based on the provisions of the Articles of Incorporation pursuant to Article 178 of the Companies Act, which was resolved at same meeting of Board of Directors.

1. Acquisition of Treasury Stock in October, 2025

(1) Class of stock acquired Common stock

(2) Total number of shares acquired 640,000 shares (on an Execution base)

(3) Total acquisition cost 1,625,075,690 yen

(4) Period of acquisition From October 1, 2025 to October 31, 2025

(5) Method of acquisition Market buying on the Tokyo Stock Exchange

2. Results of Acquisition of Treasury Stock

(1) Class of stock acquired Common stock

(2) Total number of shares acquired 3,251,000 shares

(3) Total acquisition cost 7,999,832,693 yen

(4) Period of acquisition From May 14, 2025 to October 31, 2025

(5) Method of acquisition Market buying on the Tokyo Stock Exchange

3. Cancellation of Treasury Stock

(1) Class of stock to be cancelled Common stock
(2) Total number of shares to be 3,251,000 shares

cancelled (1.48% of the total number of common stock issued before

Cancellation)

(3) Number of shares outstanding 215,975,042 shares

after the cancellation (Including Treasury Stock)

(4) Scheduled date of Cancellation November 28, 2025

Reference

Details of the resolution at the Board of Directors meeting held on May 13, 2025

1. Reasons for the acquisition and the cancellation of treasury stock

To improve capital efficiency through shareholder returns.

2. Details of the matters concerning the acquisition

(1)	Class of stock to be acquired	Common stock
(2)	Total number of shares to be acquired	Up to 4,000,000 shares (1.9% of the total number of common stock issued (excluding treasury stock))
(3)	Total acquisition cost	Up to 8 billion yen
(4)	Period of acquisition	From May 14, 2025 to October 31, 2025
(5)	Method of acquisition	Market buying on the Tokyo Stock Exchange

3. Details of the matters concerning the cancellation

(1)	Class of stock to be cancelled	Common stock
(2)	Total number of shares to be cancelled	The number corresponding to all of the treasury stock acquired through 2 above
(3)	Cancellation date	Implemented by December 31, 2025 after completion of the treasury stock acquired through 2 above

#

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.